BioCentury | Jul 31, 2020
Distillery Therapeutics

Targeting the metabolic enzyme DGAT1 to treat glioblastoma

...levels of DGAT1 protein were higher in grade IV GBM than lower grades, and high DGAT1...
...patients. In human GBM cell lines, a tool compound DGAT1 inhibitor or an shRNA against DGAT1...
...Viking Therapeutics Inc. (NASDAQ:VKTX) have DGAT1 inhibitors in preclinical testing to treat dyslipidemia. TARGET/MARKER/PATHWAY: Diacylglycerol O-acyltransferase-1 (DGAT1...
BioCentury | Nov 27, 2019
Product Development

Early Pfizer data from DGAT2-targeting NASH program lay groundwork for monotherapy and combos

Pfizer thinks Phase I and preclinical data from its DGAT2 program suggest the target could hit NASH's three mechanistic pillars -- dysregulated metabolism, inflammation and fibrosis. The pharma is advancing a next-generation compound both alone...
BioCentury | Aug 2, 2019
Product Development

Boehringer plays catch-up in NASH, dives into new modalities across the board

Although Boehringer’s recent spate of deals plug pipeline holes in fibrosis and cancer, a broader survey of the pharma’s partnering activity over the last two years shows it delving into technologies that let it jump...
BioCentury | Feb 20, 2019
Distillery Therapeutics

Autoimmune disease

...DGAT1 inhibitor decreased clinical disease scores compared with normal DGAT1 expression or vehicle, respectively, and DGAT1...
...inhibitor of DGAT1, in Phase I testing for acne. Piramal Enterprises Ltd. has P7435, a DGAT1...
...and Viking Therapeutics Inc. have DGAT1 inhibitors in preclinical testing to treat dyslipidemia. TARGET/MARKER/PATHWAY: Diacylglycerol O-acyltransferase-1 (DGAT1...
BioCentury | Nov 3, 2018
Product Development

New partners for NASH

Pharmas are loading up their NASH portfolios expecting that addressing the full disease spectrum will require combinations, though the field lacks the tools to sort the different mechanisms on offer strategically. Meanwhile, at least three...
BioCentury | Nov 2, 2018
Company News

Pfizer, Novartis in NASH deal with multiple MOAs

Pfizer Inc. (NYSE:PFE) and Novartis AG (NYSE:NVS; SIX:NOVN) partnered to test Novartis' tropifexor (LJN452) in combination with three compounds from Pfizer with different mechanisms of action to treat non-alcoholic steatohepatitis. The partners will conduct preclinical...
BioCentury | Oct 29, 2018
Company News

Pfizer, Novartis in NASH deal with multiple MOAs

Pfizer Inc. (NYSE:PFE) and Novartis AG (NYSE:NVS; SIX:NOVN) partnered to test Novartis' tropifexor (LJN452) in combination with three compounds from Pfizer with different mechanisms of action to treat non-alcoholic steatohepatitis. The partners will conduct preclinical...
BioCentury | Oct 5, 2018
Company News

Boston Pharmaceuticals licenses three Novartis antibacterials, five GSK programs

...tyrosine kinase inhibitor, to treat irritable bowel syndrome with diarrhea (IBS-D); and GSK3008356, a diacylglycerol O-acyltransferase-1 (DGAT1...
...Cambridge, Mass. Business: Pharmaceuticals Sandi Wong GSK3008356 GSK3183475 GSK3352589 IID572 LYS228 MAK181 Boston Pharmaceuticals Inc. GlaxoSmithKline plc Novartis AG Bacterial UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase (LpxC) Beta lactamase (LACTB) Diacylglycerol O-acyltransferase-1 (DGAT1) Psoriasis Pseudomonas Irritable...
BioCentury | Oct 3, 2018
Company News

Boston Pharmaceuticals licenses three Novartis antibacterials, five GSK programs

...tyrosine kinase inhibitor, to treat irritable bowel syndrome with diarrhea (IBS-D); and GSK3008356, a diacylglycerol O-acyltransferase-1 (DGAT1...
...see "Community Chorus" ). Sandi Wong Boston Pharmaceuticals Inc. GlaxoSmithKline plc Novartis AG Bacterial UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase (LpxC) Beta lactamase (LACTB) Diacylglycerol O-acyltransferase-1 (DGAT1) Psoriasis Pseudomonas Irritable...
BioCentury | Sep 21, 2017
Targets & Mechanisms

Appetite for GFRAL

Simultaneous publications from Eli Lilly and Co ., Johnson & Johnson and Novo Nordisk A/S identifying GFRAL as the receptor of the anti-obesity hormone GDF15 will undoubtedly accelerate therapeutic translation of the pathway. The race...
Items per page:
1 - 10 of 33